Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5240 - Systematic Evaluation of the Immune Microenvironment of Neuroendocrine Tumours (NET)

Date

11 Sep 2017

Session

Poster display session

Presenters

Clare Vesely

Citation

Annals of Oncology (2017) 28 (suppl_5): v1-v21. 10.1093/annonc/mdx361

Authors

C. Vesely1, A. Childs1, Y.N.S. Wong1, O. Ogunbiyi2, T.V. Luong2, C. Thirlwell3, M. Caplin3, T. Marafioti1, S.A. Quezada1, T. Meyer1

Author affiliations

  • 1 Ucl Cancer Institute, UCL - University College London, WC1B 6DD - London/GB
  • 2 Department Of Surgery, Royal Free Hospital, London/GB
  • 3 School Of Medicine, Royal Free Hospital School of Medicine, NW3 2QG - London/GB
More

Resources

Abstract 5240

Background

Immunotherapy is currently being explored in many tumour types with encouraging results, but has not yet been evaluated in neuroendocrine tumours (NET). Our aim is to characterise the immune landscape of NET and determine which immune-modulatory pathways control the tumour infiltrating lymphocytes (TILs) in order to develop a rational approach for immunotherapy in this tumour type.

Methods

Peripheral blood and fresh tissue was obtained from consenting patients with NET, and subjected to multicolour flow-cytometry to determine the abundance of CD8+, CD4+FoxP3- effector (CD4eff) and CD4+FoxP3+ regulatory (Treg) T cell subsets and the expression of co-inhibitory and co-stimulatory checkpoint molecules on these subsets. Additionally, matched FFPE tissue was obtained for multiparametric immunohistochemistry to investigate the distribution of the immune infiltrate.

Results

Tissue from 23 NET patients including 19 mid-gut tumours (13: G1 and 6: G2) was analysed. Overall the tumours contained a higher proportion of Tregs compared with peripheral blood (8.5% vs 5%, P = 0.02) and had a CD8:Treg ratio of 18.1:24.3 respectively (P = 0.036). The co-inhibitory molecules CTLA-4 and TIM-3 showed highest expression on Tregs, while PD-1 and LAG-3 expression was similar across all T cell subsets. Co-stimulatory molecules, including ICOS, 41BB and OX-40, were also highest on Tregs, as was the recently identified co-stimulatory receptor TIGIT. Immunohistochemistry revealed that the majority of cases have

Conclusions

These preliminary results provide novel insight into the immune landscape of NET, and may inform the development of targeted combination immunotherapies. Initial results suggest that checkpoint molecules, such as PD1 and LAG-3, may be potential targets in this tumour type and work is ongoing to further elucidate the immunogenic potential of NET.

Clinical trial identification

Legal entity responsible for the study

University College London

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.